Kalydeco Approved in Canada to Treat Infants 4 Months and Older

Kalydeco Approved in Canada to Treat Infants 4 Months and Older

304227

Kalydeco Approved in Canada to Treat Infants 4 Months and Older

Health Canada has extended the use of Kalydeco (ivacaftor) to treat babies, starting at 4 months old, who have cystic fibrosis (CF) caused by certain mutations. The specific gating mutations covered are: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R. Kalydeco, Vertex Pharmaceuticals, was previously approved in Canada to treat children, starting at age 1, and adults with these mutations. “With today’s approval, children in Canada as young as 4 months now have a medicine to treat the underlying…

You must be logged in to read/download the full post.